Compare Viatris Inc (VTRS) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Viatris Inc trades at $16.06 (market cap $18.49B), while YieldMax Universe Fund of Option Income ETFs trades at $7.71. The key difference: Viatris Inc pays a 2.98% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Viatris Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| VTRS | YMAX | |
|---|---|---|
Market Cap | $18.49B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $17.86 | $13.26 |
52-Week Low | $9.49 | $7.27 |
Enterprise Value | $30.61B | — |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
YMAX trades at $7.63, down 1.04% today, with a bullish technical signal but mixed momentum indicators. The ETF maintains a consistent weekly dividend distribution schedule, though recent news highlights concerns over fee structures impacting payouts. Support and resistance levels cluster around $8, indicating potential consolidation near current prices.
Outlook remains cautious due to high fees eroding yields and technical overbought signals. Risks include cost inefficiencies and dependency on market volatility for strategy performance. Analyst sentiment is mixed, balancing income appeal against structural expenses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
